OTEZLA XR - (75MG ; TABLET,EXTENDED RELEASE)

Generic Name	APREMILAST	**Innovator**	Amgen
Dosage	75MG ; TABLET,EXTENDED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: • Active psoriatic arthritis • Plaque psoriasis who are candidates for phototherapy or systemic therapy • Oral ulcers associated with Behçet's Disease. Pediatric patients 6 years of age and older with: • Active psoriatic arthritis • Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.